Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 4/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.35 |
| ▸ | RECQL | P46063 | 2/20 | 0.35 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.35 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.35 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4742842 | 0.86 | MAPT (0.35) | GLATDP1MAPTLMNAKDM4E | |
| SCHEMBL9555439 | 0.86 | MAPT (0.35) | GLATDP1MAPTLMNAKDM4E | |
| SCHEMBL11409353 | 0.82 | ADORA3 (0.45) | MAPTLMNAKDM4EHTTALDH1A1 | |
| SCHEMBL7088421 | 0.80 | KDM1A (0.36) | MAPTLMNAHTTALDH1A1CYP1A2 | |
| SCHEMBL30052413 | 0.77 | TRPA1 (0.35) | MAPTLMNAKDM4EHTTPOLB | |
| SCHEMBL8830381 | 0.76 | KDM1A (0.35) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL27919393 | 0.74 | MAPT (0.37) | GLATDP1MAPTLMNAKDM4E | |
| SCHEMBL5565774 | 0.74 | KDM1A (0.33) | MAPTLMNAHTTKMT2AMEN1 | |
| SCHEMBL30874319 | 0.73 | KDM1A (0.38) | GLATDP1MAPTLMNAKDM4E | |
| SCHEMBL28413151 | 0.73 | KDM1A (0.42) | MAPTLMNAKDM4EHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101427135-B | T cell assays | ANTITOPE LTD. (GB) | 2014-10-29 | — | — | CN | disclosed |
| EP-1989544-B1 | T CELL ASSAYS | ANTITOPE LTD (GB) | 2011-06-22 | — | — | EP | disclosed |
| US-20090221024-A1 | T CELL ASSAYS | ANTITOPE LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| CN-101427135-A | T cell assays | ANTITOPE LTD (GB) | 2009-05-06 | — | — | CN | disclosed |
| EP-1989544-A1 | T CELL ASSAYS | Antitope Limited (GB) | 2008-11-12 | — | — | EP | disclosed |
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY LTD. (AU) | 2008-10-16 | — | — | US | disclosed |
| EP-1879564-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | Astrum Therapeutics Pty, Ltd. (AU) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007099341-A1 | T CELL ASSAYS | ANTITOPE LIMITED (GB) | 2007-09-07 | — | — | WO | disclosed |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | ASTRUM THERAPEUTICS PTY LTD (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110477-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY. LTD. (AU) | 2006-10-19 | — | — | WO | disclosed |
| WO-1997038978-A1 | ANTICONVULSANT (10,11-DIHYDRO) 10-OXY-5H-DIBENZ[B,F]AZEPINE-5-CARBOXAMIDES | TRIFARMA S.R.L. (IT) | 1997-10-23 | — | — | WO | disclosed |
| US-4181655-A | ANTIDEPRESSANTS | RESEARCH INSTITUTE FOR MEDICINE AND CHEMISTRY INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | IAPP, BCL2, AMY2A | GLA 338/4885TDP1 2943/4885MAPT 531/4885 |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | IAPP, BCL2, AMY2A | GLA 338/4885TDP1 2943/4885MAPT 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.